We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
- Authors
Xue, Yibo; Meehan, Brian; Fu, Zheng; Wang, Xue Qing D.; Fiset, Pierre Olivier; Rieker, Ralf; Levins, Cameron; Kong, Tim; Zhu, Xianbing; Morin, Geneviève; Skerritt, Lashanda; Herpel, Esther; Venneti, Sriram; Martinez, Daniel; Judkins, Alexander R.; Jung, Sungmi; Camilleri-Broet, Sophie; Gonzalez, Anne V.; Guiot, Marie-Christine; Lockwood, William W.
- Abstract
Tumor suppressor SMARCA4 (BRG1), a key SWI/SNF chromatin remodeling gene, is frequently inactivated in cancers and is not directly druggable. We recently uncovered that SMARCA4 loss in an ovarian cancer subtype causes cyclin D1 deficiency leading to susceptibility to CDK4/6 inhibition. Here, we show that this vulnerability is conserved in non-small cell lung cancer (NSCLC), where SMARCA4 loss also results in reduced cyclin D1 expression and selective sensitivity to CDK4/6 inhibitors. In addition, SMARCA2, another SWI/SNF subunit lost in a subset of NSCLCs, also regulates cyclin D1 and drug response when SMARCA4 is absent. Mechanistically, SMARCA4/2 loss reduces cyclin D1 expression by a combination of restricting CCND1 chromatin accessibility and suppressing c-Jun, a transcription activator of CCND1. Furthermore, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition both in vitro and in vivo, suggesting that FDA-approved CDK4/6 inhibitors could be effective to treat this significant subgroup of NSCLCs. Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers to CDK4/6 inhibition.
- Publication
Nature Communications, 2019, Vol 10, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-019-08380-1